An Open Label Study of the Effect of First Line Treatment With Avastin (Bevacizumab) in Combination With Low-Dose Interferon on Progression-Free Survival in Patients With Metastatic Clear Cell Renal Cell Carcinoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 23 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Interferon alpha-2a (Primary)
Indications Renal cell carcinoma
Focus Therapeutic Use
Acronyms BEVLIN
Sponsors Roche

Most Recent Events

18 Dec 2021 This trial has been completed in Italy, according to European Clinical Trials Database.(3 Feb 2012)
25 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
26 May 2015 Primary and secondary endpoints are amended.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight